Business
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
VICTORIA, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences\n\n\n\n VICTORIA, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company’s management team will present and participate at the following upcoming investor conferences:\n \n\n\n Canaccord Growth 45th Annual Growth Conference\n \n\n Date: August 12 - 14, 2025\n \n Presentation date & time: August 13, 2025, 9:30am ET\n \n Location: Boston, MA\n \n\n\n Citi Biopharma Back to School Conference\n \n\n Date: September 2-3, 2025\n \n Location: Boston, MA\n \n\n\n Cantor Global Healthcare Conference\n \n\n Date: September 3-5, 2025\n \n Presentation date & time: September 5, 2025, 9:10am ET\n \n Location: New York, NY\n \n\n\n H.C. Wainwright 27th Annual Global Investment Conference\n \n\n Date: September 8-10, 2025\n \n Location: New York, NY\n \n\n\n About Eupraxia Pharmaceuticals Inc.\n \n\n\n Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestina...